文献速递结核与非结核分枝杆菌艾滋病与性传播感染

电子剂量监测识别耐药结核合并HIV治疗中的高风险亚群

Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus.
PubMed 文献 · Clin Infect Dis · 2021-01-01

在南非夸祖鲁-纳塔尔省开展的前瞻性研究,纳入198例接受含贝达喹啉方案的耐药结核合并HIV患者,用电子剂量监测装置分别测量贝达喹啉和抗逆转录病毒治疗的依从性。32例(16%)被识别为双重依从性挑战者,仅领取残疾补助与6个月时双重不依从显著相关,该亚群HIV病毒载量可检测率和死亡率更高。

要点

  • 电子剂量监测可在治疗早期经验性识别双重依从性挑战的DR-TB/HIV患者。
  • 双重依从性挑战者HIV病毒载量可检测率和死亡率高于依从性较好患者。
  • 干预应聚焦心理社会与结构性障碍,提供以患者为中心的差异化支持。

核心结论

  • 电子剂量监测可在治疗早期经验性识别DR-TB合并HIV患者中双重依从性挑战的亚群。
  • 该亚群存在严重心理社会、行为和结构性障碍,HIV病毒载量可检测率和死亡率更高。

研究设计与样本

  • 前瞻性研究,在南非夸祖鲁-纳塔尔省纳入198例接受含贝达喹啉方案且正在抗逆转录病毒治疗的DR-TB合并HIV患者。
  • 使用独立电子剂量监测装置分别测量贝达喹啉和抗逆转录病毒治疗的依从性,将两者依从性均低于85%者定义为高风险。
  • 结合基线调查、研究访视记录和焦点小组讨论进行混合方法分析。

主要发现

  • 在纳入基线特征的多变量模型中,仅领取残疾补助与6个月时双重不依从显著相关。
  • 混合方法识别出酒精滥用、家庭冲突和心理健康问题等治疗障碍。
  • 与依从性较好患者相比,双重依从性挑战者更难优先安排治疗且缺乏支持,HIV病毒载量可检测率和死亡率更高。

关键数值与推荐

  • 双重依从性挑战定义为对贝达喹啉和抗逆转录病毒治疗的依从性均低于85%。

临床怎么用

  • 可考虑用电子剂量监测早期识别DR-TB合并HIV中双重依从性挑战的高风险患者。
  • 对识别出的亚群应提供聚焦心理社会与结构性障碍的差异化、以患者为中心的支持干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In generalized drug-resistant tuberculosis (DR-TB) human immunodeficiency virus (HIV) epidemics, identifying subpopulations at high risk for treatment failure and loss to care is critically important to improve treatment outcomes and prevent amplification of drug resistance. We hypothesized that an electronic dose-monitoring (EDM) device could empirically identify adherence-challenged patients and that a mixed-methods approach would characterize treatment challenges. METHODS: A prospective study of patients with DR-TB HIV on antiretroviral therapy (ART) initiating bedaquiline-containing regimens in KwaZulu-Natal, South Africa. Separate EDM devices measured adherence for bedaquiline and ART. Patients with low adherence (<85%) to both bedaquiline and ART were identified as high risk for poor outcomes. Baseline survey, study visit notes, and focus group discussions characterized treatment challenges. RESULTS: From December 2016-February 2018, 32 of 198 (16%) enrolled patients with DR-TB HIV were identified as dual-adherence challenged. In a multivariate model including baseline characteristics, only receiving a disability grant was significantly associated with dual nonadherence at 6 months. Mixed-methods identified treatment barriers including alcohol abuse, family conflicts, and mental health issues. Compared with adherent patients, dual-adherence-challenged patients struggled to prioritize treatment and lacked support, and dual-adherence-challenged patients experienced higher rates of detectable HIV viral load and mortality than more adherent patients. CONCLUSIONS: EDM empirically identified a subpopulation of patients with DR-TB HIV with dual-adherence challenges early in treatment. Mixed-methods revealed intense psychosocial, behavioral, and structural barriers to care in this subpopulation. Our data support developing differential, patient-centered, adherence support interventions focused on psychosocial and structural challenges for subpopulations of at-risk DR-TB HIV patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zelnick JR, Daftary A, Hwang C, et al. Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 33053186. doi:10.1093/cid/ciaa1557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。